UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 323

Sortiert nach

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

The New England journal of medicine, 2018-06, Vol.378 (26), p.2475-2485

2018

Volltextzugriff (PDF)

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

The New England journal of medicine, 2018-06, Vol.378 (26), p.2486-2496

2018

Volltextzugriff (PDF)

Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Ophthalmology (Rochester, Minn.), 2016-03, Vol.123 (3), p.655-662

2016

Volltextzugriff (PDF)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Journal of gastroenterology, 2014-02, Vol.49 (2), p.283-294

2014

Volltextzugriff (PDF)

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

The Journal of dermatological treatment, 2020-08, Vol.31 (6), p.606-614

2020

Volltextzugriff (PDF)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease

Pharmacy, 2022-07, Vol.10 (4), p.87

2022

Volltextzugriff (PDF)

Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system

PloS one, 2019-12, Vol.14 (12), p.e0225572

2019

Volltextzugriff (PDF)

Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis

PloS one, 2019-01, Vol.14 (1), p.e0210517-e0210517

2019

Volltextzugriff (PDF)

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

Gastroenterology (New York, N.Y. 1943), 2008-11, Vol.135 (5), p.1493-1499

2008

Volltextzugriff (PDF)

Increased Risks of Developing Anxiety and Depression in Young Patients With Crohn's Disease

The American journal of gastroenterology, 2011-09, Vol.106 (9), p.1670-1677

2011

Volltextzugriff (PDF)

Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial

The American journal of gastroenterology, 2008-12, Vol.103 (12), p.3132-3141

2008

Volltextzugriff (PDF)

Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons

Clinical therapeutics, 2017-04, Vol.39 (4), p.849-862.e6

2017

Volltextzugriff (PDF)

The costs of Crohn's disease in the United States and other Western countries: a systematic review

Current medical research and opinion, 2008-02, Vol.24 (2), p.319-328

2008

Volltextzugriff (PDF)

Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors

Current medical research and opinion, 2017-11, Vol.33 (11), p.1945-1953

2017

Volltextzugriff (PDF)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Acta dermato-venereologica, 2021-11, Vol.101 (11), p.adv00585-adv00585

2021

Volltextzugriff (PDF)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Acta dermato-venereologica, 2021-07, Vol.101 (7), p.adv00504-adv00504

2021

Volltextzugriff (PDF)

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Dermatology and therapy, 2023-09, Vol.13 (9), p.2107-2120

2023

Volltextzugriff (PDF)

Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family

JEADV clinical practice, 2024-03, Vol.3 (1), p.253-257

2024

Volltextzugriff (PDF)

Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus

Clinical therapeutics, 2007, Vol.29 (1), p.177-180

2007

Volltextzugriff (PDF)

Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial

The American journal of gastroenterology, 2009-05, Vol.104 (5), p.1170-1179

2009

Volltextzugriff (PDF)

Efficacy of dupilumab in moderate and severe atopic dermatitis

JEADV clinical practice, 2023-06, Vol.2 (2), p.247-260

2023

Volltextzugriff (PDF)

Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years

Journal of patient-reported outcomes, 2022-05, Vol.6 (1), p.55-55, Article 55

2022

Volltextzugriff (PDF)

32929 Dupilumab decreases concomitant therapy use in adults with atopic dermatitis (AD): Long-term data from the RELIEVE-AD study

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB45-AB45

2022

Volltextzugriff (PDF)

33120 Early and sustained improvement in atopic dermatitis (AD) disease control and treatment satisfaction with dupilumab in clinical practice: Long-term data from the RELIEVE-AD study

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB47-AB47

2022

Volltextzugriff (PDF)

Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis

JAMA ophthalmology, 2016-11, Vol.134 (11), p.1237

2016

Volltextzugriff (PDF)

1 – 25 von 323

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(286)
Mit Volltextzugriff
(237)

Publikationsform

Sprache

Englisch
(322)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease

Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system

Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

Increased Risks of Developing Anxiety and Depression in Young Patients With Crohn's Disease

Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial

Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons

The costs of Crohn's disease in the United States and other Western countries: a systematic review

Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family

Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus

Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial

Efficacy of dupilumab in moderate and severe atopic dermatitis

Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years

32929 Dupilumab decreases concomitant therapy use in adults with atopic dermatitis (AD): Long-term data from the RELIEVE-AD study

33120 Early and sustained improvement in atopic dermatitis (AD) disease control and treatment satisfaction with dupilumab in clinical practice: Long-term data from the RELIEVE-AD study

Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis

Suchergebnisse filtern